Jingzhong Ouyang

Jingzhong Ouyang

Auto-generated profile, based on publicly available information

Jingzhong Ouyang

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2022 in Journal of Hepatology
Verified
Journal Article
Open access
PDF file
YYYi Yang
Yi Yang
JOJingzhong Ouyang
Jingzhong Ouyang
YZYanzhao Zhou
Yanzhao Zhou
ZJZhou Jinxue
Zhou Jinxue
HZHong Zhao
Hong Zhao
This study was supported by the National Natural Science Foundation of China (No. 81972311 , 82141127 ), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-1-066 ), and the Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences (No. 2019PT310026 ).

14 September 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
YYYeng Ye
Yeng Ye
ZWZhengzheng Wang
Zhengzheng Wang
ZJZhou Jinxue
Zhou Jinxue

1 September 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
ZWZhengzheng Wang
Zhengzheng Wang
KYKun Yuan
Kun Yuan
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
ZJZhou Jinxue
Zhou Jinxue
Purpose: To evaluate the efficacy and safety of lenvatinib plus programmed death-1 (PD-1) antibody as postoperative adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risks of recurrence. Patients and Methods: A series of 137 patients with HCC at high risks of recurrence who underwent hepatectomy at our hospital between October 2019 and January 2022 were retrospectively analyzed. Recurrence-free survival (RFS), overall survival (OS), and treatment-related adverse events (TRAEs) were assessed. Landmark analysis was used to compare short- and long-term RFS. Univariable and multivariable analyses were used to identify prognostic factors, and subgroup analyses were performed according to high risks of recurrence. Results: A total of 85 patients underwent hepatectomy alone and 52 patients received postoperative adjuvant therapy. Compared with the hepatectomy group (HG), RFS was significantly improved in the adjuvant therapy group (ATG) (P < 0.001), but OS was not (P = 0.098). Landmark analysis revealed that RFS within 6 months of the HG was significantly different from that of the ATG (P < 0.001) but not after 6 months (P = 0.486). Multivariable analysis showed that without adjuvant therapy, high Child-Pugh classification, high alpha-fetoprotein levels, microvascular invasion, and satellite lesions were independent risk factors for recurrence within 6 months after hepatectomy. Subgroup analysis revealed that patients with MVI significantly benefited from adjuvant therapy in RFS. But for OS, adjuvant therapy was only significantly effective in patients with single tumor. The most common treatment-related adverse events during adjuvant therapy were hypertension (36.5%), rash or itching (28.8%), diarrhea (23.1%), and fatigue (21.2%). Conclusion: Postoperative adjuvant lenvatinib plus PD-1 antibody significantly improved RFS in patients with HCC at high risks of recurrence with acceptable safeties.

1 June 2024 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
YZYanzhao Zhou
Yanzhao Zhou
JOJingzhong Ouyang
Jingzhong Ouyang
HYHongcai Yang
Hongcai Yang
ZWZhengzheng Wang
Zhengzheng Wang
YYYi Yang
Yi Yang
QLQiang Li
Qiang Li
Purpose: The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions. Patients and Methods: Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan-Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models. Results: A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS (P = 0.001). The protections of VATI (P = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared (P = 0.146), but the effect of SMD on OS did not (P = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI. Conclusion: This study first demonstrated that high VATI and mid-level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.

1 August 2024 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
JOJingzhong Ouyang
Jingzhong Ouyang
YYYi Yang
Yi Yang
YZYanzhao Zhou
Yanzhao Zhou
XCXu Chang
Xu Chang
ZWZhengzheng Wang
Zhengzheng Wang
HZHong Zhao
Hong Zhao
Original Article Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study Jingzhong Ouyang, Yi Yang, Yanzhao Zhou, Xu Chang, Zhengzheng Wang, Qingjun Li, Yu Tang, Jianqiang Cai, Jinxue Zhou, Zhen Huang, Hong Zhao

2 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
JOJingZhong OuYang
JingZhong OuYang
YZYanzhao Zhou
Yanzhao Zhou
ZWZhengzheng Wang
Zhengzheng Wang
QLQingjun Li
Qingjun Li
JZJinxue Zhou
Jinxue Zhou
Background:Advanced hepatocellular carcinoma (HCC) with Portal vein invasion has an extremely dismal prognosis. We report a rare case of advanced HCC with portal vein tumor thrombus (PVTT). First, Lenvatinib(Len) combined with Toripalimab(Tor) was treated. The patient was successfully treated with radical surgical resection after the tumor thrombus shrank. Postoperative pathology showed complete response (CR).Case presentation:A 52-year-old male patient had a massive liver cancer in his right liver, and the tumor thrombus grew to the main portal vein. He passed 4 cycles of Len combined with Tor, the tumor shrank rapidly, the level of tumor markers dropped rapidly, The tumor thrombus was successfully confined from the main portal vein to the right branch of the portal vein. Therefore, the patient underwent a right hepatectomy and successfully removed a complete PVTT. Histopathological results showed that the primary tumor and tumor thrombus were only infiltrated by inflammatory cells, and there were no viable tumor cells.Conclusions:Len combined with Tor can be used as a preoperative neoadjuvant regimen for the treatment of advanced HCC with massive macrovascular invasion.